Bio Connections Australia explores drug development, early phase clinical trials, translational research and expediting Australia’s great science into commercialization. It comes at a critical time for Australia’s medical research sector.
The focus of the agenda this year will be on translation and commercialization of homegrown Australian research, improving drug development and clinical trials in Australia as well as the impact of COVID-19 on the landscape.
Bio Connections Australia provides an important platform for further discussion and debate on what the challenges, opportunities and realities may be for drug development, clinical trials and medical research in Australia.
BioCurate CEO Dr C. Glenn Begley will be on the Panel Discussion: How Do we Get More Australian Programs into Clinical Trials from Homegrown IP?